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Background: DDX39B (BAT1) encodes an RNA helicase known to regulate expression of TNF and IL-6. Elevated
levels of these two cytokines are associated with increased severity of clinical malaria. The aim of this study was to
investigate the relationship between single nucleotide polymorphisms (SNPs) in the DDX39B, TNF and IL6 genes and
the clinical outcomes of patients with Plasmodium vivax malaria.
Methods: Cross-sectional investigations were carried out in two regions of the Brazilian Amazon where several studies
on the pathogenesis of vivax malaria had been performed. Individuals were categorized according to infection status
as well as clinical presentation into the following groups: uninfected, asymptomatic infection, mild infection, or
complicated infection. Polymorphisms were identified using PCR restriction fragment-length polymorphism analysis
and the restriction enzymes NlaIII or NcoI. The plasma levels of cytokines were determined using ELISA.
Results: The G allele of DDX39B-22C > G was associated with absent or decreased manifestations of malaria and the C
allele was a risk factor for disease complications. Study participants heterozygous for TNF-308 (GA) and DDX39B-348 (CT)
had higher TNF levels than wild-type participants. Haplotypes that included DDX39B (−22C > G and -348C > T) and TNF
polymorphisms were not directly associated with mild or complicated malaria infections; however, haplotypes AGC,
ACC, GGT, AGT and ACT were associated with increased TNF levels. Participants with genotype combinations GC/CC/
GG/GG and GG/CT/GG/GG (DDX39B-22/DDX39B-348/TNF-308/IL6-176) had decreased and increased risk of mild malaria,
respectively, compared with asymptomatic and uninfected participants. GC/CC/GG/GG was linked to decreased TNF
and IL-6 levels.
Conclusions: This is the first study to describe patients with DDX39B and IL6 SNPs who had vivax malaria. These
findings support the postulation that a set of mutations in immune-related genes is associated with inflammatory
mediators and the clinical outcomes of patients with malaria.
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Plasmodium vivax malaria is a major worldwide threat,
with two to three billion people remaining at risk of infec-
tion [1]. The clinical outcomes of patients with vivax mal-
aria range from asymptomatic infection to complicated,
and potentially lethal disease [2]. The risk for progression* Correspondence: mbarral@bahia.fiocruz.br
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article, unless otherwise stated.of severe Plasmodium falciparum malaria has been
thought to be partly accounted for by host genetic factors
[3]. These genetic factors are likely to involve several gen-
etic alterations in immune mediators as well as molecules
involved in mechanisms of cytoadherence and haemoglobi-
nopathies [4]. Understanding the key host genetic determi-
nants of susceptibility to malaria is critical for developing
better therapies and vaccine strategies.
The nuclear protein HLA-B-associated transcript 1
(BAT1) is an RNA helicase encoded by the DDX39B gene
(DEAD [Asp-Glu-Ala-Asp] box polypeptide 39B, alsotral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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regulator of inflammation by modulating expression of
proinflammatory cytokines, such as TNF and IL-6, which
suggests that it plays a protective role in several immune-
mediated disorders [5]. The -22C >G and -348C >T poly-
morphisms in the promoter region of DDX39B have been
shown to affect its transcriptional activity and the binding
of nuclear transcription factors such as YY1 and Oct1 oli-
gonucleotides at the respective positions −348 and −22
relative to the transcription start site of DDX39B [6]. TNF
(=TNFalpha or TNFA) and IL-6 are key mediators associ-
ated with malaria symptoms, and their levels are increased
in proportion to the severity of disease [7-12]. The hypoth-
esis that DDX39Bmay have an effect on the clinical presen-
tation of malaria by its modulation of the expression of
proinflammatory cytokines involved in the pathogenesis of
the disease is appealing, but has not yet been tested.
Single nucleotide polymorphisms (SNPs) in the TNF
(−308G > A) and IL6 (−176G > C) genes may regulate
the plasma levels of these cytokines; however, the mech-
anism of regulation is not yet fully understood [13-15].
Given the major role of the host immune system in P.
vivax infection, the aim of this study was to determine
whether mutations in the DDX39B, TNF and IL6 genes
were associated with the clinical outcomes of patients
with vivax malaria. The frequency of SNPs in DDX39B
(−22C > G and -348C > T), TNF (−308G > A) and IL6
(−176G > C) were compared between P. vivax-infected
study participants who exhibited different clinical out-
comes, including asymptomatic infection, mild malaria,
complicated malaria, and no infection. Associations be-
tween these immune-related mutations and plasma levels
of TNF, IL-6, C-X-C motif chemokine 10 (CXCL10), and
C-reactive protein (CRP) were also tested. The results re-
ported here revealed that a combination of DDX39B, TNF
and IL6 host genotypes were associated with manifesta-




This report describes series of patients from two distinct
studies. The first study performed retrospective analyses of
cryopreserved heparinized blood samples from participants
living in riverine communities of the state of Rondônia, in
the Brazilian Western Amazon, who were recruited be-
tween 2006 and 2007, as previously described [7,16-23].
Malaria was diagnosed using two methods: 1) microscopic
examination of a thick blood smear performed by profes-
sionals at the Brazilian National Foundation of Health
(FUNASA); and 2) polymerase chain reaction (PCR) per-
formed at the Oswaldo Cruz Foundation (FIOCRUZ),
Salvador, Brazil, as previously described [16-18]. The study
included individuals who had been living in the endemicarea for more than six months. Exclusion criteria included
conditions known to interfere with the parameters evalu-
ated in this report, such as coinfections and chronic dis-
eases: P. falciparum infection confirmed by nested PCR;
documented or referred viral hepatitis (hepatitis A, B, C, D
virus [HAV, HBV, HCV, HDV]); chronic alcoholism; human
immunodeficiency virus (HIV) infection; yellow fever; den-
gue; leptospirosis; tuberculosis; Hansen disease; visceral
leishmaniasis; cancer and/or other chronic degenerative
disease; sickle cell trait; and the use of hepatotoxic and im-
munosuppressant drugs. A total of 257 participants were
enrolled in this first part of the study. As reported previ-
ously, all asymptomatic participants infected with P. vivax
who were identified by active case detection were moni-
tored for 30 days for the evaluation of malaria manifesta-
tions [16-18]. Participants who were positive for P. vivax
infection but remained without acute febrile signs for
30 days were considered to be asymptomatic cases. Those
individuals with positive parasitaemia and with mild symp-
toms were considered to have mild vivax malaria. Thus, the
individuals from this region were divided into three groups
as follows: mild malaria (n = 76), asymptomatic malaria
(n = 104) and uninfected controls (n = 77). All symptomatic
cases were treated following the guidelines of the National
Foundation of Health, Brazil, and received chloroquine for
three days and primaquine (0.5 mg/kg/day) for seven days.
The asymptomatic carriers were treated after the monitor-
ing period, as reported previously [17]. This first part of the
study was approved by the Ethics Committee of the São
Lucas University, Rondônia, Brazil; and all participants pro-
vided written informed consent.
Participants with complicated Plasmodium vivax malaria
Because there was a small number and unavailable blood
samples of malaria cases (n = 9) with signs/symptoms of
complicated disease among the first series of patients re-
cruited in Rondonia, in order to evaluate the role of
DDX39B (BAT1) polymorphism in complicated cases of
vivax malaria, a second series of patients (second part of
this report) was recruited from the state of Amazonas in
the Western Brazilian Amazon between 2009 and 2013.
Individuals of all ages who were hospitalized with an un-
identified acute febrile syndrome at the reference hos-
pital from the Fundação de Medicina Tropical Dr Heitor
Vieira Dourado (FMT-HVD), Amazonas, Brazil, were
tested for malaria using microscopic examination of a
thick blood thick smear, and those with PCR-confirmed
P. vivax were recruited. Patients were excluded for the
following conditions: microscopic or molecular diagnosis of
P. falciparum or P. vivax and P. falciparum malaria (mixed
infection), serologic diagnosis of viral hepatitis (HAV, HBV,
HCV, and HDV), HIV, or leptospirosis. Patients with vivax
malaria with primaquine-induced haemolysis (patients
taking primaquine with decreasing haemoglobin levels
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direct bilirubin levels after primaquine treatment) were also
excluded. The study participants from this second series
had either mild signs/symptoms of acute malaria (mild mal-
aria, n = 69) or clinical complications, as listed in Table 1
(complicated vivax malaria, n = 31). Complicated vivax mal-
aria was defined according to the criteria for severe mal-
aria from the World Health Organization (WHO) or
based on the presence of hyperbilirubinaemia (serum totalTable 1 Characteristics of the second series of participants wi











1 M 59 hyperbilirubinaemia No
2 F 38 hyperlactemia Yes
3 M 31 hyperbilirubinaemia No
4 F 37 hyperbilirubinaemia No
5 M 18 hyperbilirubinaemia No
6 M 45 severe anaemia hyperbilirubinaemia No
7 F 40 severe anaemia No
8 M 66 convulsion Yes
9 M 17 hyperbilirubinaemia No
10 M 31 hyperbilirubinaemia No
11 M 1 severe anaemia No
12 M 26 hyperbilirubinaemia No
13 F 4 months convulsion prostration No
14 M 19 severe anaemia No
15 M 50 respiratory failure No
16 F 35 severe anaemia hyperbilirubinaemia No
17 F 41 respiratory failure No
18 F 18 hyperbilirubinaemia No
19 M 44 severe anaemia Yes
20 F 23 severe anaemia Yes
21 M 5 prostration No
22 M 21 hyperbilirubinaemia Yes
23 M 12 respiratory failure Yes
24 F 74 respiratory failure No
25 M 37 respiratory failure Yes
26 F 26 hyperbilirubinaemia No
27 M 53 hyperbilirubinaemia No
28 F 36 hyperbilirubinaemia No
29 F 15 severe anaemia Yes
30 M 22 hyperbilirubinaemia No
31 M 25 hyperbilirubinaemia Yes
Severe anaemia was defined as haemoglobin levels below 7 g/dL for adults and below
Respiratory failure was defined as tachypnea, shortness of breath, mental confusion clin
indicates participants who already started malaria therapy before the blood sample collebilirubin > 51.3 μmol/L) [24]. Although all the participants
in this second study were PCR positive, some of these
study patients with complicated malaria (just for this par-
ticular group) had already started therapy for malaria be-
fore blood samples were taken, which might have affected
the results of the laboratory and parasitaemia evaluations
shown in Table 1. This second part of the study was ap-
proved by the Ethics Committee of the FMT-HVD, and all









6,222 7 16.9 403.56
0 10 10.9 30.78
3,298 10 11.0 54.72
67,467 7 8.9 51.30
1,848 4 13.5 165.87
243 10 6.5 138.51
33,553 10 7.0 27.36
185 14 13.0 *
226 6 11.9 53.01
5,937 15 13.5 165.87
38,712 9 5.0 8.55
128 2 10.6 61.56
108,033 7 11.7 *
0 17 6.5 15.39
310 5 10.1 8.55
34,673 1 4.8 138.51
24,815 8 9.9 39.33
670 5 11.7 61.56
0 7 6.9 13.68
264 8 6.4 6.84
291 15 8.2 6.84
832 7 9.7 102.6
0 6 7.8 15.39
325 5 11.7 29.07
0 10 7.1 17.10
254 9 11.3 140.22
45,833 6 11.8 59.85
0 3 7.9 85.50
8,894 8 6.9 11.97
3,054 7 15.1 73.53
27,954 3 15.0 138.51
5 g/dL for children and hyperbilirubinaemia by serum total bilirubins >51.3 μmol/L.
ical signs of hypoxaemia (central and/or peripheral cyanosis). Previous treatment
ction. *Total bilirubin was not measured in these individuals.
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DNA was extracted from 200 μL of peripheral blood
using a standard Qiagen DNA blood mini kit (Valencia,
CA, USA) according to the manufacturer’s protocol. The
SNPs at positions −22 (C > G) (rs2239527; G ancestral
allele) and −348 (C > T) (rs2239528 ;C ancestral allele)
in the promoter region of DDX39B and at position −176
of IL6 (G > C) (rs2234683; G ancestral allele) were typed
using PCR restriction fragment-length polymorphism ana-
lysis with the restriction enzyme NlaIII (New England Bio-
labs), according to protocols previously published by
Ramasawmy et al. [25] and Yalcin et al. [26], respectively.
TNF-308 (G > A) (rs1800629; G ancestral allele) poly-
morphism was also evaluated using PCR restriction
fragment-length polymorphism analysis with the restric-
tion enzyme NcoI (New England Biolabs), as published
previously [27]. DDX39B and TNF PCR products were
electrophoresed on 10% polyacrylamide gels and IL6 prod-
ucts were separated by electrophoresis on 1% agarose gels
under nondenaturing conditions. The PCR products were
then detected by staining with ethidium bromide and visu-
alized under ultraviolet illumination.
Plasma measurements
The plasma levels of IL-6, CXCL10, and TNF were mea-
sured using a cytometric bead array system (BD Biosci-
ences Pharmingen, Franklin Lakes, NJ, USA) according to
the manufacturer’s protocol. CRP levels in plasma were
measured using the turbidimetric immunoassay method,
performed at the Federal University of Bahia and Facul-
dade São Lucas, Brazil.
Statistical analysis
Categorized variables (genotypes, alleles, haplotypes, and
genotype combinations) were compared using the Chi-
square test or Fisher exact test in 2x2 contingency tables
along with the relevant odds ratio (OR) and 95% confi-
dence interval (CI). Univariate linear regression analysis
was performed to assess the associations between com-
binations of genotypes and malaria symptomatology. Or-
dinal variables were evaluated using the Mann–Whitney
(between two groups) or Kruskal-Wallis test followed by
the Dunn multiple comparison test or trend analysis
(when more than two groups were compared). Hardy-
Weinberg equilibrium (HWE) was assessed for the dif-
ferent groups by comparing the observed number of dif-
ferent genotypes with those expected under HWE for the
estimated allele frequency. The power of this study was
calculated based on a medium effect size, a significance
level of 0.05, and four degrees of freedom (Chi-square
test). A power of 98.3% was found for the first series of
participants (n = 257) and a power of 71.10% for the sec-
ond series of participants (n = 110). Statistical analyses
were performed using GraphPad Prism (version 5.0b)software (GraphPad Software, San Diego, CA, USA) or R
version 2.15.1 (The R Foundation for Statistical Comput-
ing, Vienna, Austria).
Results
Baseline characteristics of first series of participants
All different groups of vivax malaria infection had a
slightly majority of women. Participants with asymptom-
atic malaria were older than the uninfected participants
and those with mild malaria (P = 0.0264; Table 2). Partic-
ipants with asymptomatic malaria reported a higher
number of previous infections (median 15.0, interquartile
range (IQR) 12.00-18.75) than the uninfected participants
or those with mild infection (P < 0.0001; Table 2). In
addition, participants with asymptomatic P. vivax infection
reported living for a longer time in the endemic area
(71.15% more than ten years) than those in the other
groups (P = 0.0030; Table 2). These results were expected,
since this set of patients was a subsample of a larger cohort
of individuals where similar results were found [7,16-23].
Single nucleotide polymorphisms
Genotype and allele distributions of IL6-176G > C and
TNF-308G > A polymorphisms were compared in the
main clinical groups and in participants stratified ac-
cording to mild vs asymptomatic vivax malaria infection,
infected vs uninfected and asymptomatic vs uninfected
(Table 3). No association was found between alleles or
genotypes of IL6 and TNF SNPs and the different clinical
outcomes of vivax malaria (Table 3). The distributions of
IL6-176G >C and TNF-308G >A genotypes in all categor-
ies were under HWE. Table 4 shows the results for
DDX39B polymorphisms (−22C >G and -348C >T) ac-
cording to the same categories of participants (Table 4). No
differences were observed for the SNPs DDX39B-22C >G
and DDX39B-348C >T with regard to mild malaria,
asymptomatic malaria, or infection status. The distribution
of DDX39B-22C >G in the asymptomatic participants was
not under HWE (x2 = 6.10, P = 0.0134), suggesting those
participants reflect evolutionary selective pressure. The fre-
quencies of DDX39B genotypes were under HWE in all the
other categories of vivax malaria infection.
Association of single nucleotide polymorphisms with
inflammatory mediators levels
The SNPs were assessed regarding association with sys-
temic levels of TNF, IL-6, CXCL10, and CRP, which
have been associated with vivax malaria manifestations
[23]. Participants with the TNF-308 GA genotype or A
allele had higher levels of TNF than those with the GG
genotype or G allele (P = 0.0347 and P = 0.0296, respect-
ively, Figure 1A,B). Participants with the DDX39B-348
CT genotype or T allele had higher concentrations
of TNF than those with the CC genotype or C allele




malaria (n = 104)
Mild vivax
malaria (n = 76)
P value
Male - no. (%) 36 (46.75) 47 (45.19) 36 (47.37) 0.9548**
Median (IQR*) age (yr) 35.00 (25.50-45.00) 42.00 (32.00-49.00) 36.00 (27.25-50.00) 0.0264***
Median (IQR*) of previous malaria episodes 12.00 (6.00-17.00) 15.00 (12.00-18.75) 6.00 (1.00-12.75) <0.0001***
Time residing in the area (yr)
≤2 17 (22.08) 24 (23.08) 24 (31.58) 0.0011**
3 to 10 19 (24.67) 6 (5.77) 16 (21.05)
>10 41 (53.25) 74 (71.15) 36 (47.37)
* IQR, interquantile range; **Categorized variables were compared using Chi-square test; ***Ordinal variables were compared using the Kruskal-Wallis test with the
Dunn multiple comparison test
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morphism at DDX39B-22 appeared to correlate with serum
concentrations of CRP and CXCL10, but not IL-6. Partici-
pants with the DDX39B-22 CC genotype exhibited higher
levels of CRP than those with the GC genotype (P = 0.0395,
Figure 1C) but this difference was not observed in the allele
analysis (P = 0.0622, Figure 1D). No relevant associations
were found between genotypes or alleles of DDX39B-22
C >G and plasma IL-6 levels (P = 0.0496 and P = 0.7475,
respectively, Figure 1E,F). Furthermore, participants carry-
ing the DDX39B-22 CG genotype had lower CXCL10 levels
than those with the GG genotype (P = 0.0294, Figure 1E),
although no difference was seen in the allele analysis
(P = 0.0898, Figure 1F).Table 3 TNF (−308G > A) and IL-6 (−176G > C) polymorphisms
participants from Rondonia, Brazil
Genotype χ2
GG n (%) GA n (%) AA n (%)
TNF-308 polymorphism
Uninfected (n = 77) 60 (77.92) 15 (19.48) 2 (2.60) 2.12 p
Asymptomatic malaria (n = 104) 78 (75.00) 25 (24.04) 1 (0.96)
Mild malaria (n = 76) 54 (71.05) 21 (27.63) 1 (1.32)
Infected vs uninfected p = 0.3
Mild vs asymptomatic p = 0.6
Asymptomatic vs uninfected p = 0.5
Genotype χ2
GG n (%) GC n (%) CC n (%)
IL6-176 polymorphism
Uninfected (n = 77) 49 (63.64) 23 (29.87) 5 (6.49) 2.16 p
Asymptomatic malaria (n = 104) 60 (57.69) 38 (36.54) 6 (5.77)
Mild malaria (n = 76) 40 (52.63) 30 (39.47) 6 (7.90)
Infected vs uninfected 1.56 p
Mild vs asymptomatic 1.30 p
Asymptomatic vs uninfected 0.88 p
*In these cases, Fisher exact test was used. #Analysis excluded genotype AA. χ2: coe
represent symptomatic plus asymptomatic cases.Haplotypes and combinations of genotypes
DDX39B and TNF are located in the same major histo-
compatibility complex (MHC) region on chromosome 6,
and therefore assessment of the association of these poly-
morphisms with the outcomes of malaria can be per-
formed using haplotype analysis. The assessment of
haplotypes representing all possible combinations of TNF-
308, DDX39B-22 and DDX39B-348 SNPs was unable to
identify significant association with any of the clinical cat-
egories of vivax malaria infection (Figure 2A). Nevertheless,
haplotypes were associated with differential expression of
inflammatory mediators in plasma, which could potentially
influence the degree of immunopathology and malaria
manifestations. TNF-308, DDX39B-22, and DDX39B-348and outcome of vivax malaria infection: first series of
Allele frequency χ2 GG vs GA+AA χ2
G (%) A (%)
= 0.7134# 135 (87.66) 19 (12.34) 0.57 p = 0.7509 0.96 p = 0.6178
181 (87.02) 27 (12.98)
129 (84.87) 23 (15.13)
401*# p = 0.6745* P = 0.5316*
059*# p = 4798* P = 0.4323*
866*# p = 8749* P = 0.7252*
Allele frequency χ2 GG vs GC + CC χ2
G (%) C (%)
= 0.7058 121 (78.57) 33 (21.43) 1.61 p = 0.4462 1.91 p = 0.3854
158 (75.96) 50 (24.04)
110 (72.37) 42 (27.63)
= 0.4579 p = 0.3695* p = 0.2702*
= 0.5214 p = 0.2618* p = 0.2711*
= 0.6435 p = 0.0819* p = 0.4458*
fficient and P value measured using Chi-square test. Infected individuals
Table 4 DDX39B polymorphisms (−22C > G and -348C > T) and outcome of vivax malaria infections: first series of
participants from Rondonia, Brazil
Genotype χ2 Allele frequency χ2 CC vs CG + GG χ2
CC n (%) CG n (%) GG n (%) C (%) G (%)
DDX39B-22 polymorphism
Uninfected (n = 77) 10 (12.99) 38 (49.35) 29 (37.66) 6.75 p = 0.1496 58 (37.66) 96 (62.34) 2.35 p = 0.3088 0.53 p = 0.7660
Asymptomatic malaria (n = 104) 15 (14.42) 64 (61.54) 25 (24.04) 94 (45.19) 114 (54.81)
Mild malaria (n =7 6) 13 (17.10) 34 (44.74) 29 (38.16) 60 (39.47) 92 (60.53)
Infected vs uninfected 1.48 p = 0.4758 p = 0.3281* p = 0.2460*
Mild vs asymptomatic 2.90 p = 0.2339 p = 0.6244* p = 0.7028*
Asymptomatic vs uninfected 3.98 p = 0.1364 p = 0.1625* p = 0.8307*
Genotype Allele frequency CC vs TC + TT χ2
CC n (%) TC n (%) TT n (%) C (%) T (%)
DDX39B-348 polymorphism
Uninfected (n = 77) 64 (83.12) 12 (15.58) 1 (1.30) 1.99 p = 0.3691# 140 (90.91) 14 (9.09) 1.00 p = 0.6041 1.56 p = 0.4586
Asymptomatic malaria (n = 104) 83 (79.81) 21 (20.19) 0 (0.00) 187 (89.90) 21 (10.10)
Mild malaria (n = 76) 57 (75.00) 19 (25.00) 0 (0.00) 133 (87.50) 19 (12.50)
Infected vs uninfected p = 0.2397*# p = 0.5342* p = 0.4012*
Symptomatic vs asymptomatic p = 0.2372*# p = 0.3469* p = 0.3108*
Asymptomatic vs uninfected p = 0.5594*# p = 0.8578* p = 0.7008*
*In these cases, Fisher exact test was used. #Analysis excluded genotype TT. χ2: coefficient and P value measured using Chi-square test. Infected individuals
represent symptomatic plus asymptomatic cases.
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trations of CRP and CXCL10, respectively, than other hap-
lotypes (P = 0.0246, Figure 2B; P = 0.0071, Figure 3C;
respectively). Intriguingly, several haplotypes were associ-
ated with increased plasma TNF levels (Figure 2D). Thus,
because they were found to be associated with elevated or
decreased levels of CRP, CXCL10, and TNF, haplotypes
may be associated with the outcomes of vivax malaria
infection.
Analysis of combinations of genotypes was performed
to determine association with manifestations of vivax
malaria. Participants with DDX39B-22/DDX39B-348/
TNF-308/IL6-176 genotype combinations GC/CC/GG/
GG and GG/CT/GG/GG had decreased and increased
risk, respectively, of developing manifestations of mal-
aria relative to asymptomatic participants (OR 0.41,
95% CI 0.17-0.98, P = 0.0428; OR 4.77, 95% CI 1.10-
20.59, p = 0.0361; respectively, Figure 3A). Moreover,
the genotype combination GC/CC/GG/GG was associ-
ated with lower TNF and IL-6 levels than other genotypes
(P = 0.0070 and P = 0.0057, respectively; Figure 3B,C), sug-
gesting that this set of genotypes may protect against more
severe malaria because of association with reduced levels
of inflammatory cytokines.
Second series of study participants: DDX39B
polymorphisms and complicated vivax malaria
An additional aim of this combined study was to specif-
ically evaluate the association between DDX39Bpolymorphisms and complicated P. vivax malaria. Pa-
tients screened in a reference hospital from the Brazil-
ian Amazon who manifested complicated malaria were
compared with those presenting with mild disease. Par-
ticipants with mild malaria had a median age of 36 years
(IQR 27–46) and 81.16% were male (n = 56). Participants
with complicated disease had a similar age (median
31 years, IQR 18–41; P = 0.0563) and there was a slightly
lower proportion of males (19 of 31 [61.29%], P = 0.0460).
Characteristics of the patients with complicated malaria
are shown in Table 1. Interestingly, the patients in this
study who were categorized with complicated vivax mal-
aria exhibited more often hyperbilirubinaemia (serum total
bilirubin >51.3 μmol/L), which has been reported to be a
common complication of patients with vivax malaria
[28,29].
There was significant difference in the distribution fre-
quency of the polymorphism DDX39B-22C >G in the par-
ticipants with mild versus complicated malaria (x2 = 6.72,
P = 0.0347). The proportion of -22C homozygosity among
patients with complicated and mild malaria was 25.80%
(n = 8) and 7.25% (n = 5), respectively (Table 5). Partici-
pants were categorized based on the presence or absence
of the G allele (genotypes GG and GC vs genotype CC)
and the G allele was significantly more frequent in patients
with mild vivax malaria than in patients with complicated
infection (P = 0.0207, Table 5). No differences were seen
for the polymorphism DDX39B (−348C > T) regarding the
distribution of genotypes and alleles in patients with mild
Figure 1 Influence of genetic alterations on levels of inflammatory mediators. Each symbol represents a single patient, and the lines
represent medians and interquartile range. (A) Levels of TNF according to genotypes of TNF-308G > A and DDX39B-348C > T polymorphisms.
Analysis excluded TT (DDX39B-348C > T), because only 1 uninfected participant had this genotype. (B) Levels of TNF according to alleles of
TNF-308G > A and DDX39B-348C > T polymorphisms. (C) CRP plasma levels according to different DDX39B-22C > G genotypes. (D) CRP plasma levels
according to different DDX39B-22C > G alleles. (E) IL-6 and CXCL10 levels according to DDX39B-22C > G genotypes. (F) IL-6 and CXCL10 levels according
to DDX39B-22C > G alleles. The data were compared using the Mann–Whitney test (comparisons between two groups), the Kruskal-Wallis test with
Dunn multiple comparisons or linear trend analysis (comparisons between more than 2 groups). P values are shown in each panel.
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DDX39B-22C >G genotypes in the patients with mild
malaria was not under HWE (x2 = 5.22, P = 0.0222). The
DDX39B genotypes were under HWE in the patients with
complicated malaria.
Discussion
Immunity of the human host to malaria is likely to be me-
diated by T-cell recognition of Plasmodium sp. epitopes on
infected host cells via class I and II MHC antigens [30].
Given the importance of the MHC to the immune re-
sponse, genetic studies of the human MHC I have corre-
lated polymorphisms in this region with susceptibility to
malaria. The alleles A*30:01 and A*33:01 of MHC I were
found to be associated with malaria severity in Mali
[30-32]. The DDX39B (BAT1) gene is located on chromo-
some 6 near the TNF gene in the same MHC region andseems to influence expression of several immune-related
genes [6]. This study found that the C allele of DDX39B-
22C >G is a potential risk factor of complicated vivax mal-
aria in the Brazilian Amazon. This finding may be expected,
as this allele has been associated with reduced binding to
transcription factors and expression of inflammatory cyto-
kines [5]. Haplotype analysis (including DDX39B and TNF
polymorphisms) found that genetic alterations in these
immune-mediated genes may influence disease outcome by
altering TNF plasma levels. In addition, the genotype com-
binations GC/CC/GG/GG and GG/CT/GG/GG, corre-
sponding to the respective polymorphisms DDX39B-22/
DDX39B-348/TNF-308/IL6-176, were associated with a de-
creased or increased risk, respectively, of developing mild
vivax malaria, probably by altering TNF and IL-6 levels. To
the best of our knowledge, this is the first report assessing
the relationship between DDX39B polymorphisms and
Figure 2 Haplotype influence on inflammatory mediators and outcomes of malaria infection. Each symbol represents a single patient, and
the lines represent medians and interquartile range. (A) The figure represents all the possible haplotypes for TNF-308G > A, DDX39B-348C > T, and
DDX39B-22C > G polymorphisms. Haplotypes were compared between the 3 categories of vivax malaria infections (uninfected, asymptomatic,
mild malaria). (B) CRP levels in participants with GGC haplotype compared to individuals with other haplotypes. (C) CXCL10 plasma concentration
in participants with GCC haplotype compared to individuals with other haplotypes. (D) TNF levels in participants with different haplotypes. Each
haplotype was compared with participants with other haplotypes. The differences between groups illustrated in (A) were compared using the
chi-square test. The data in (B), (C), and (D) were compared using the Mann–Whitney test. P values are shown in each panel.
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analyze the manifestations of P. vivax infections in relation
to combinations of immune-related genotypes.
Plasma concentrations of IL-6 have been found to be as-
sociated with severe disease and death from malaria, and
the IL6-176C allele was associated with increased expres-
sion of IL-6 in neonates and adults developing acute phase
reactions [14,15,33,34]. A study of sympatric ethnic groups
in Mali found that the frequency of IL6 CG/GG genotypes
was higher in non-Fulani ethnic groups, who have in-
creased susceptibility to malaria, in both symptomatic and
asymptomatic falciparum malaria cases [35]. However, in
our study, there were no differences in the distribution ofIL6-176G > C in the participants making up the different
clinical groups of vivax malaria, which may indicate that
this polymorphism plays different roles in P. vivax infection
and/or in a Brazilian population. Genetic changes in TNF
have been described in several studies of different popula-
tions throughout the world, and there have sometimes been
contradictory results [23]. The SNP TNF-308G >A has
been associated with increased susceptibility, resistance or
there has been no association with severity to malaria
caused by P. falciparum [36-39]. A study of a population in
the Brazilian Amazon that was similar to our population
found that one TNF haplotype (TNF-1031T/-863A/-857T/-
308G/-238G) including the TNF-308G allele was associated
Figure 3 Genotype combinations and outcomes of malaria infection. (A) Univariate linear regression analysis of the different combination of
TNF-308G > A, IL6-176G > C, DDX39B-348C > T, and DDX39B-22C > G genotypes. The odds ratios and respective 95% confidence intervals (95% CI)
are shown according to each combination of genotypes compared with the other combinations. (B-C) Each symbol represents a single patient,
and the lines represent medians and interquartile range. TNF and IL-6 levels in participants with the GC/CC/GG/GG combination compared with
the other combinations. The data were compared using the Mann–Whitney test. P values are shown in each panel.
Table 5 DDX39B polymorphisms (−22C > G and -348C > T) and complicated vivax malaria infections: second series of
participants from Amazonas, Brazil
Genotype χ2 Allele frequency χ2 CC vs CG + GG χ2
CC n (%) CG n (%) GG n (%) C (%) G (%)
DDX39B-22 polymorphism
Mild malaria (n = 69) 5 (7.25) 41 (59.42) 23 (33.33) 6.72 p = 0.0347 51 (36.96) 87 (63.04) p = 0.0628* p = 0.0207*
Complicated malaria (n = 31) 8 (25.80) 16 (51.61) 7 (22.58) 32 (51.61) 30 (48.39)
Genotype Allele frequency CC vs TC + TT χ2
CC n (%) TC n (%) TT n (%) C (%) T (%)
DDX39B-348 polymorphism
Mild malaria (n = 69) 55 (79.71) 14 (20.29) 0 (0.00) p = 7,850*# 124 (89.86) 14 (10.14) p = 0.7965* p = 7,850*
Complicated malaria (n = 31) 26 (83.87) 5 (16.13) 0 (0.00) 57 (91.93) 5 (8.07)
*In these cases, Fisher exact test was used. #Analysis excluded genotype TT. χ2: coefficient and P value measured using Chi-square test.
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http://www.malariajournal.com/content/13/1/278with increased susceptibility to mild vivax malaria [40]. Our
study did not find an association between TNF-308G and
clinical manifestations of malaria. It is noteworthy that
TNF-308G >A may not be a causal mutation, and that this
polymorphism could be in linkage disequilibrium with
other causal mutations located close to the TNF gene [41].
Thus, this polymorphism may have a moderate effect or
may have an epistatic effect on DDX39B mutations [42].
Polymorphisms in DDX39B (BAT1) have been described in
several diseases with inflammatory profiles, including neur-
opathy, myasthenia gravis, allergies, Alzheimer disease,
myocardial infarction, hepatitis, rheumatoid arthritis,
Chagas disease, among others [25,43-48]. In this study it
was found that the G allele of DDX39B-22C >G may be a
resistance factor to malaria and the C allele a risk factor for
disease complications. It has been reported that DDX39B
promoter polymorphisms alter the binding of transcrip-
tion factors (YY1 and Oct1) and may affect the transcrip-
tion of this gene, and the sequences with -22G and -348 T
alleles were expressed more efficiently than sequences
containing -22C and-348C alleles [6]. An in vitro study
found that BAT1 appeared to decrease the expression of
TNF and IL-6 [5]; thus the G allele of DDX39B-22C >G,
which enhances the expression of BAT1, may be protect-
ive against complicated malaria by decreasing the expres-
sion of proinflammatory cytokines.
Although the polymorphisms described in this study are
not directly associated with the clinical manifestations of
malaria, they can indirectly influence disease by altering the
levels of inflammatory mediators involved in disease immu-
nopathology. High plasma levels of TNF are related to the
pathogenesis of signs associated with malaria, such as fever,
and severe forms of infection, such as cerebral malaria and
severe anemia [49]. Our study found that participants het-
erozygous (AG) for TNF-308G >A had higher plasma con-
centrations of TNF than homozygous participants with the
wild-type (GG) polymorphism. The A allele of this SNP has
been associated with increased production of TNF in sev-
eral studies, and was often associated with the HLA-A1-
B8-DR3 haplotype of the MHC region [50-53]. In this study
results did not clearly demonstrate increased levels of TNF
in participants homozygous for the A mutation, probably
because of the small number of participants with this geno-
type who were recruited for the study. Furthermore, partici-
pants heterozygous (CT) for DDX39B-348C >T had higher
plasma TNF than homozygous participants with the wild-
type (CC) polymorphism, suggesting that an additional gen-
etic mechanism appears to be associated with increased
levels of this cytokine, and consequently the clinical out-
come of malaria infection. CRP is an acute-phase inflam-
matory protein, and this study findings indicate that
participants homozygous (CC) for DDX39B-22 (G >C) had
increased levels of CRP, supporting an association of the C
allele with risk of complicated malaria.A single-point mutation is often not sufficient for pre-
dicting the susceptibility or resistance of individuals to
malaria [4]. Another approach to investigating the differ-
ences in response to malaria infection is haplotype analysis
of mutant alleles. DDX39B is situated in the central region
of MHC on the short arm of human chromosome 6 and is
approximately 150 kb from the TNF gene. The NFKBIL1
gene, which encodes the inhibitor of κB-like protein
(IκBL), a protein of unknown function, is situated between
DDX39B and TNF [54]. Genetic variations in NFKBIL1
are associated with susceptibility to inflammatory condi-
tions such as periodontitis, chronic thromboembolic pul-
monary hypertension, rheumatoid arthritis, and malaria
[54-58]. Although DDX39B and TNF genes are near each
other on the same chromosome and appear to influence
the transcription of its gene products [5], this study did
not identify a haplotype with DDX39B (22C >G and 348C
> T) and TNF-308G >A polymorphisms that increased
the risk of clincal vivax malaria. However, many haplo-
types appear to markedly increase TNF levels, indirectly
contributing to malaria susceptibility. It is noteworthy that
conclusive findings from DDX39B and TNF haplotype
analysis are limited by the considerable distance between
these genes (approximately 150 kb). Similarly, it is re-
ported here an analysis of susceptibility to clinical mani-
festations of malaria as a result of genotype combinations
found that CG/CC/GG/GG and GG/CT/GG/GG, corre-
sponding to the respective polymorphisms DDX39B-22/
DDX39B-348/TNF-308/IL6-176, were associated with de-
creased and increased risk, respectively, of developing
clinical manifestations of P. vivax infection. Intriguingly,
TNF-308 and IL6-176 genotypes were wild-type homozy-
gotes (GG for both) among the combinations, and changes
were related to DDX39B genotypes. The substitution of
DDX39B genotypes (−22 and −348) in the combinations
completely changed the risk of developing manifestations
of malaria, from susceptibility to resistance to illness from
vivax malaria infections. These results lend support to the
role of DDX39B as a regulatory gene that can alter tran-
scription factors and inflammatory cytokines and influence
the clinical outcome of inflammatory diseases [5,25]. More-
over, study participants with the genotype combination de-
scribed here that was associated with resistance against
manifestations of P. vivax infection (CG/CC/GG/GG) also
had lower levels of proinflammatory TNF and IL-6, sug-
gesting that DDX39B confers protection against malaria
pathogenesis by reducing the inflammatory response.
This study was limited because of a small numbers of
participants, which may have reduced its ability to detect
significant differences between study groups. Indeed, the
detection of a small difference (effect size) between groups
at a significance level of 0.05 ideally would require at least
1,194 study participants. Therefore, our study results re-
quire validation in larger studies.
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Genetic alterations in the immune response against vivax
malaria may predispose individuals to disease complications
or protect them from clinical disease. The findings of this
study provide support that the C allele of DDX39B-22C >G
is a risk factor of complicated vivax malaria, and different
haplotypes (including DDX39B and TNF polymorphisms)
may influence disease outcomes by altering plasma levels
of TNF. Moreover, the results suggest that combinations
of genotypes (including IL6-176G > C) are associated with
a decreased or increased risk of developing clinical mani-
festations of malaria and may also influence plasma TNF
and IL-6 levels. Further prospective studies should be able
to determine if these genetic determinants are critical for
protection against the development of clinical P. vivax in-
fection, and also identify individuals who are at risk of de-
veloping more complicated forms of malaria.
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